. 2021 Feb 10;2021:6617575. doi: 10.1155/2021/6617575

Table 1.

Ulcer characteristic at baseline, after 3 months, and after 6 months.

Ulcer characteristic	Groups	Baseline		First follow-up after 3 months		Second follow-up after 6 months
Ulcer characteristic	Groups	Mean ± standard deviation	P value	Mean ± standard deviation	P value	Mean ± standard deviation	P value
Average size of ulcer	Placebo	4.75 ± 0.55	0.079	4.65 ± 0.48	0.082	4.6 ± 0.50	<0.0001^∗
Average size of ulcer	Omega-3	5.11 ± 0.70	0.079	4.37 ± 0.48	0.082	3.5 ± 1.27	<0.0001^∗
Average number of ulcer	Placebo	2.65 ± 0.81	0.06	2.45 ± 0.75	0.018^∗	2.45 ± 0.75	<0.0001^∗
Average number of ulcer	Omega-3	3.6 ± 0.88	0.06	1.9 ± 0.64	0.018^∗	1.35 ± 0.67	<0.0001^∗
Average duration of ulcer (in weeks)	Placebo	8.83 ± 1.47	0.389	8.83 ± 1.47	<0.0001^∗	8.57 ± 1.51	<0.0001^∗
Average duration of ulcer (in weeks)	Omega-3	9.69 ± 0.63	0.389	4.94 ± 0.93	<0.0001^∗	3.84 ± 2.03	<0.0001^∗
Ulcer free period (in weeks)	Placebo	3.05 ± 0.68	0.07	3.1 ± 0.71	0.657	3.1 ± 0.71	<0.005^∗
Ulcer free period (in weeks)	Omega-3	2.55 ± 0.60	0.07	3.2 ± 0.69	0.657	3.7 ± 1.94	<0.005^∗
Pain	Placebo	7.3 ± 1.34	1	7.2 ± 1.39	0.075	7.2 ± 1.36	<0.0001^∗
Pain	Omega-3	8.15 ± 1.30	1	4.9 ± 0.96	0.075	3.65 ± 1.78	<0.0001^∗
Mucosal site	Placebo	4.15 ± 0.93	0.474	3.75 ± 0.85	<0.0001^∗	3.75 ± 0.78	<0.0001^∗
Mucosal site	Omega-3	4.4 ± 1.23	0.474	2.85 ± 2.3	<0.0001^∗	2 ± 1.02	<0.0001^∗
USS^ꞷ (ulcer severity score)	Placebo	31.1 ± 2.61	0.08	30.35 ± 2.3	<0.0001^∗	30.3 ± 2.29	<0.0001^∗
USS^ꞷ (ulcer severity score)	Omega-3	33.36 ± 2.02	0.08	25.75 ± 4.53	<0.0001^∗	14.95 ± 6.25	<0.0001^∗

^∗ P value is significant; ^ꞷulcer severity score.